Guidance for industry IND exemptions for studies of lawfully marketed drug or biological products for the treatment of cancer.
| Other Authors: | Center for Drug Evaluation and Research (U.S.), Center for Biologics Evaluation and Research (U.S.) |
|---|---|
| Format: | Electronic |
| Language: | English |
| Published: |
Rockville, MD :
U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research,
[2004]
|
| Physical Description: |
1 online resource (8 pages) |
| Subjects: | |
| Online Access: |
https://purl.fdlp.gov/GPO/LPS116353 |
| Item Description: |
"Center for Biologics Evaluation and Research (CBER)." "Clinical medical." "Revision 1." "January 2004." GPO Cataloging Record Distribution Program (CRDP). |
|---|---|
| Physical Description: |
1 online resource (8 pages) |